article thumbnail

Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to Acquire the Company’s Digital Pathology Business

Healthcare IT Today

Future releases of Dynamyx will also create opportunities for Fujifilm to support pharmaceutical and contract research organizations with toxicity testing data management for drug development. “A Source: Markets and Markets “Digital Pathology Market, Global Forecast to 2025”; Signify Research “Digital Pathology – World – 2018”.

article thumbnail

Virtual Care – negotiating barriers to adoption offers glimpses of an exciting future

Lloyd Price

It stated: ‘By 2025, global spend on digital health is predicted to reach €1tn and digital products and services will grow to a market share of 12% (Choueiri et al., Digital health companies can help identify new drug targets, design clinical trials and analyse data more effectively.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FemTech: The rise of Female Health innovation

Lloyd Price

CVC’s recent acquisition of the women’s health division of the Israeli drug developer Teva for $800m created a company dedicated to contraception, fertility, menopause and osteoporosis. Recent analysis from Frost and Sullivan shows this market to be worth up to $50bn by 2025.

article thumbnail

Digital Health Technologies in Clinical Trials

Digital Health Global

Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drug development. in 2020, with projections suggesting up to 70% of clinical trials incorporating wearable sensors by 2025.